ClinicalTrials.gg
RecruitingNCT07719972Updated Nov 10, 2026

Universal Newborn Screening For Sickle Cell Disease In Mozambique

An interventional study of Point-of-care testing (POCT) -Patient participants and Point-of-care testing (POCT) - Healthy control participants in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in Mozambique. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 10, 2026Now RecruitingFirst site in Mozambique+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,750
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.

Planned enrollment
Largest of 22
6,750 · median 45
Started
2026
with 3 others
No phase
6 of 45
4 open now
Primary completion
2031-08
later than 13 of 16 live
Registered
45th of 45
by date

Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one has the largest planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 45th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

The overarching goal of this study is to evaluate the feasibility of a new methodology that combines three multi-level implementation strategies to optimize the population-level uptake of essential evidence-based, standard of care treatments for infants with sickle cell disease (SCD) in low-resource settings. The study will be done in Mozambique.

Read the detailed description

This prospective mixed-methods hybrid effectiveness-implementation feasibility study will evaluate the feasibility and effectiveness of an implementation strategy package designed to improve early diagnosis and care entry for children born with sickle cell disease (SCD) in rural, low-resource settings. The implementation strategy package includes three components: 1) integration of essential products into national supply chain systems, 2) integration of systematic newborn screening using point-of-care-testing into clinical site workflows and 3) linkage of children who screen positive to a PEN-Plus Non-Communicable Disease (NCD) clinic for longitudinal care. Participants will be tracked longitudinally to evaluate protocol adoption over time and clinical outcomes among participating children at 2 years of age.

Primary Objective

  • To test if combining three multi-level implementation strategies can facilitate systematic birth diagnosis and timely linkage to evidence-based care interventions for infants with SCD in under-resourced settings.

Secondary Objectives (Micro level):

  • To test the clinical effectiveness of implementing the BB-SCD through the three combined implementation strategies to prevent excess mortality of children with SCD under the age of 2 years.
  • To evaluate the effectiveness of combining the three implementation strategies to promote care retention among infants with SCD by 2 years of age.

Secondary Objectives (Meso level)

  • To evaluate the institutional coverage and health facility staff adoption of the treatment for infants through the combined implementation strategies.
  • To evaluate the need for a confirmatory test among positive and negative screening results using POCT.
  • To conduct a cost-effectiveness analysis of the combined implementation strategies.

Secondary Objective (Macro level)

  • To evaluate the operational effectiveness of integrating the procurement of SCD consumables into national supply chain systems to achieve sustainable availability, effective last mile delivery to relevant clinics and stockout avoidance.
03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Mozambique
  • Patient participants
  • Healthy control participants
  • Health facility staff participants
  • Supply chain expert participants
  • National public health system expert participants
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children participants: All infants between birth and 6.0 months of age who are born or receive care at secondary-level facilities involved in the UNIQUE study.
  • Children participants will fall into one of two categories:

    • Patient participants: All infants between birth and 6.0 months of age who were screened through the UNIQUE study and tested positive for SCD (HbSS, HbSC, or other form of SCD) or had indeterminate results.
    • Healthy control participants: Infants between birth and 6.0 months of age who screen negative for SCD (HbAA) through the UNIQUE study or tested positive for sickle cell trait (HbAS).
  • Health facility staff participants: Healthcare staff ages ≥18 years working at secondary-level facilities involved in the UNIQUE study.
  • Supply chain expert participants: Administrative professionals with experience working in or around the national supply chain systems in Mozambique to support procurement, importation, customs clearance, storage, and in-country distribution of medical products.
  • National public health system expert participants: Administrative professionals with experience working in the national public health system (e.g., Ministry of Health, MISAU) who oversee the delivery of health services to infants in-country, such as neonatal testing and vaccination programs.

Exclusion criteria

Exclusion Criteria:

  • Children participants:

    • Stillbirths.
    • Children who received an erythrocyte (blood) transfusion within 3 months of testing. Exogenous (transfused) HbA could artificially lower the sickle concentration, thus causing false-negative results.
  • Patient participants: none
  • Healthy control participants:

    • Stillbirths.
    • Children who received an erythrocyte (blood) transfusion within 3 months of testing. Exogenous (transfused) HbA could artificially lower the sickle hemoglobin concentration, thus causing false-negative results.
  • Health facility staff participants: none.
  • Supply chain expert participants: none.
  • National public health system expert participants: none.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,750 participants (estimated)

Study arms

  • Other
    Patient participants

    All infants between birth and 6.0 months of age who were screened through the UNIQUE study and tested positive for SCD (HbSS, HbSC, or other form of SCD) or had indeterminate results.

    Other: Point-of-care testing (POCT) -Patient participants

  • Other
    Healthy control participants

    Infants between birth and 6.0 months of age who screen negative for SCD (HbAA) through the UNIQUE study or tested positive for sickle cell trait (HbAS).

    Other: Point-of-care testing (POCT) - Healthy control participants

  • Other
    Health facility staff participants

    Healthcare staff ages ≥18 years working at secondary-level facilities involved in the UNIQUE study.

    Other: Context Assessment for Community Health (COACH) survey · Other: Semi-structured interview

  • Other
    Supply chain expert participants

    Administrative professionals with experience working in or around the national supply chain systems in Mozambique to support procurement, importation, customs clearance, storage, and in-country distribution of medical products.

    Other: Semi-structured interview

  • Other
    National public health system expert participants

    Administrative professionals with experience working in the national public health system (e.g., Ministry of Health, MISAU) who oversee the delivery of health services to infants in-country, such as neonatal testing and vaccination programs.

    Other: Semi-structured interview

Interventions

  • OtherPoint-of-care testing (POCT) -Patient participants

    Infants will be screened for Sickle Cell Disease using with point-of-care testing (POCT).

  • OtherPoint-of-care testing (POCT) - Healthy control participants

    Infants will be screened for Sickle Cell Disease using with point-of-care testing (POCT) and prospectively monitored for survival.

  • OtherContext Assessment for Community Health (COACH) survey

    The COACH survey will collect quantitative data on eight contextual factors that impact a site's ability to implement evidence-based interventions.

  • OtherSemi-structured interview

    Interview questions will revolve primarily around the current process for SCD screening and care referrals, factors impacting newborn care delivery and screening, and challenges to integrating SCD newborn screening and care referral into standard care delivery.

06

What researchers measure

Primary outcomes

  1. Percentage of eligible population screened for Sickle Cell Disease

    Time frame: 3 years

  2. Percentage of new SCD cases linked to care

    Time frame: 3 years

Secondary outcomes

  1. Comparison of under-2 mortality between participants with SCD whom received longitudinal care and participants who screened negative for SCD

    The primary outcome measure will be 'Alive and in care: Yes or No'.

    Time frame: 2 years post-screening and therapy

  2. Percentage of SCD cases retained in care by 2 years of age

    Time frame: 2 years post-screening and therapy

  3. Percentage of eligible secondary-level clinical wards implementing systematic screening and linkage to longitudinal care for new SCD cases

    Time frame: 3 years

  4. Percentage of eligible health facility staff participants in secondary-level clinical wards implementing systematic screening and linkage to longitudinal care for new SCD cases

    Time frame: 3 years

  5. Comparison of SCD Screening Performance Results from Initial point-of-care (POCT), Gazelle, and Hemoglobin Fractionation

    Investigators will estimate the sensitivity (proportion of diseased subjects that yield a positive test result) and specificity (the proportion of non-diseased subjects that yield a negative test result) of the POCT for detecting SCD compared to the gold standard with basic proportions.

    Time frame: 3 years

  6. Cost-Effectiveness of Integrating SCD Consumables into National Supply Chains

    The standard formula known as incremental cost-effectiveness ratios (ICERs) will be used. ICER is a summary statistic used in economic evaluations to compare the relative value of different healthcare interventions. It is scored by comparing the resulting cost-per-QALY against a predefined threshold, where lower ICERs indicate better value.

    Time frame: 2 to 5 years

  7. Cost-Effectiveness of POCT for Early SCD Diagnosis

    The standard formula known as incremental cost-effectiveness ratios (ICERs) will be used. ICER is a summary statistic used in economic evaluations to compare the relative value of different healthcare interventions. It is scored by comparing the resulting cost-per-QALY against a predefined threshold, where lower ICERs indicate better value.

    Time frame: 2 to 5 years

  8. Cost-Effectiveness of Decentralized PEN-Plus SCD Management

    The standard formula known as incremental cost-effectiveness ratios (ICERs) will be used. ICER is a summary statistic used in economic evaluations to compare the relative value of different healthcare interventions. It is scored by comparing the resulting cost-per-QALY against a predefined threshold, where lower ICERs indicate better value.

    Time frame: 2 to 5 years

  9. Frequency of SCD Supply Stockouts at Study Sites

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Hospital Rural de Nhamatanda
    Nhamatanda, Sofala, Mozambique
    Recruiting
    • Edi R Fulai, MD, MSC · Contact(258) 824978644
    • Ana O Mocumbi, MD, PhD, FESC · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2031, 59 months after the start.

Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 59 months is above that.

Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartActual
Sep 24, 2026was Aug 2026
Primary completionEst.
Aug 2031
CompletionEst.
Aug 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added — first site in Mozambique
Show site
  • Hospital Rural de Nhamatanda · Nhamatanda, Mozambique
Nov 10, 2026
Start date
Aug 2026→Sep 24, 2026 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Mozambique
    Show site
    • Hospital Rural de Nhamatanda · Nhamatanda, Mozambique
    Start date Aug 2026→Sep 24, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07719972
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Sep 24, 2026
Primary completion
Aug 2031 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Jane Hankins, MD
Contact
referralinfo@stjude.org
888-226-4343
Jane Hankins, MD
principal investigator · St. Jude Children's Research Hospital
Ana O. Mocumbi, MD PhD FESC
principal investigator · Eduardo Mondlane University, National Institute of Health, Chronic Disease Determinants Program

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion